161 related articles for article (PubMed ID: 22011483)
1. Use of intravitreal anti-VEGF: retinopathy of prematurity surgeons' in Hamlet's dilemma?
Azad R; Dave V; Jalali S
Indian J Ophthalmol; 2011; 59(6):421-2. PubMed ID: 22011483
[No Abstract] [Full Text] [Related]
2. REPORT OF SAFETY OF THE USE OF A SHORT 32G NEEDLE FOR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINOPATHY OF PREMATURITY: A Multicenter Study.
Cernichiaro-Espinosa LA; Harper CA; Read SP; Wright LM; Scribbick FW; Young R; Negron CI; Rodríguez A; Berrocal AM
Retina; 2018 Jun; 38(6):1251-1255. PubMed ID: 29689029
[No Abstract] [Full Text] [Related]
3. Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.
Mireskandari K; Collins ME; Tehrani N
Can J Ophthalmol; 2015 Dec; 50(6):409-12. PubMed ID: 26651298
[No Abstract] [Full Text] [Related]
4. Persistent Angiographic Abnormalities After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.
Shah N; Gupta MP; Chan RVP
JAMA Ophthalmol; 2018 Apr; 136(4):436-437. PubMed ID: 29285531
[No Abstract] [Full Text] [Related]
5. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?
Spandau U
Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079
[No Abstract] [Full Text] [Related]
6. Retrolental Hemorrhage in Berger's Space After Intravitreal Bevacizumab Injection for Retinopathy of Prematurity.
Shah PR; Sachan A; Chandra P
J Pediatr Ophthalmol Strabismus; 2020 Oct; 57():e71-e73. PubMed ID: 33090229
[TBL] [Abstract][Full Text] [Related]
7. Late-onset tractional fibrovascular proliferation post-intravitreal bevacizumab following treatment of retinopathy of prematurity.
Agarwal-Sinha S; Guevara JG; Amin SM
Can J Ophthalmol; 2018 Jun; 53(3):e99-e103. PubMed ID: 29784188
[No Abstract] [Full Text] [Related]
8. A new syringe adaptor for intravitreal injection of premature eye.
Kimura S; Tsukamoto M; Shiode Y; Hosogi M; Morizane Y
Retina; 2013 Apr; 33(4):889-90. PubMed ID: 23481457
[No Abstract] [Full Text] [Related]
9. How Does the Standard of Care Evolve? Anti-Vascular Endothelial Growth Factor Agents in Retinopathy of Prematurity Treatment as an Example.
Chiang MF
Ophthalmology; 2018 Oct; 125(10):1485-1487. PubMed ID: 30243329
[No Abstract] [Full Text] [Related]
10. Retinopathy of Prematurity Reactivated 28 Months after Injection of Ranibizumab.
Ji MH; Moshfeghi DM; Callaway NF; Bodnar Z; Schachar IH; Amorelli GM; Orazi L; Molle F; Lepore D
Ophthalmol Retina; 2019 Oct; 3(10):913-915. PubMed ID: 31474514
[No Abstract] [Full Text] [Related]
11. Prolonged follow-up period following intravitreal bevacizumab injection for stage 3+ retinopathy of prematurity.
de Klerk TA; Park DY; Biswas S
Eye (Lond); 2013 Oct; 27(10):1218. PubMed ID: 23846376
[No Abstract] [Full Text] [Related]
12. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy.
Tran KD; Cernichiaro-Espinosa LA; Berrocal AM
Asia Pac J Ophthalmol (Phila); 2018; 7(1):56-62. PubMed ID: 29376233
[TBL] [Abstract][Full Text] [Related]
13. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity.
Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A
J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065
[TBL] [Abstract][Full Text] [Related]
14. Globe size and bevacizumab treatment in retinopathy of prematurity: should we adjust the dose?
Connor AJ; Shafiq A
Eye (Lond); 2016 Nov; 30(11):1401-1403. PubMed ID: 27472209
[No Abstract] [Full Text] [Related]
15. Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab.
Tseng CC; Chen SN; Hwang JF; Lin CJ
J Pediatr Ophthalmol Strabismus; 2012 Aug; 49 Online():e41-3. PubMed ID: 22881829
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
17. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies.
Park SW; Jung HH; Heo H
Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062
[No Abstract] [Full Text] [Related]
18. Bilateral Total Cataract After Intravitreal Bevacizumab Injection in Aggressive Posterior Retinopathy of Prematurity.
Khokhar S; Chandra P; Gupta Y; Kumawat D; Dhull C
J Pediatr Ophthalmol Strabismus; 2019 Mar; 56():e28-e30. PubMed ID: 30907975
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.
VanderVeen DK; Cataltepe SU
Semin Perinatol; 2019 Oct; 43(6):375-380. PubMed ID: 31174872
[TBL] [Abstract][Full Text] [Related]
20. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
Eldweik L; Mantagos IS
Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
